Spyre Therapeutics (SYRE) CEO awarded 528,000 stock options over four years

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. reported that its Chief Executive Officer and director, Turtle Cameron, received a grant of stock options on 01/09/2026. The award covers 528,000 stock options, each representing the right to purchase one share of Spyre Therapeutics common stock at an exercise price of $30.61 per share, with an expiration date of 01/09/2036.

According to the filing, these options will vest in equal monthly installments over four years, and each vesting date is conditioned on Cameron’s continued employment with the company. Following this grant, Cameron beneficially owns 528,000 derivative securities directly in the form of these stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Turtle Cameron

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	528,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 528,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.61	01/09/2026		A		528,000		(1)	01/09/2036	Common Stock	528,000	$0	528,000	D

Explanation of Responses:

1. This option represents a right to purchase 528,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report in this Form 4?

The filing reports that Chief Executive Officer and director Turtle Cameron received a grant of 528,000 stock options to buy Spyre Therapeutics common shares.

What is the exercise price and term of the Spyre Therapeutics CEO stock options?

The stock options granted to Turtle Cameron carry an exercise price of $30.61 per share and have an expiration date of 01/09/2036.

How do the 528,000 Spyre Therapeutics CEO stock options vest?

The 528,000 stock options will vest in equal monthly installments over four years, with each installment requiring Cameron’s continued employment on the applicable vesting date.

How many derivative securities does the Spyre Therapeutics CEO own after this transaction?

After the reported grant, Turtle Cameron beneficially owns 528,000 derivative securities, all in the form of these stock options, held directly.

Is the reported Spyre Therapeutics insider transaction a purchase or a grant?

The transaction is reported with code A, indicating an award or grant of stock options to the Chief Executive Officer, rather than an open-market purchase or sale.

What roles does Turtle Cameron hold at Spyre Therapeutics (SYRE)?

Turtle Cameron is identified as both a Director and an Officer, serving as the company’s Chief Executive Officer.